Paul Schimmel, a director at ATYR Pharma (NASDAQ:ATYR), purchased 100,000 common shares on May 27, 2026, for a total of $49,630.
The shares were acquired at prices between $0.4907 and $0.50 per share, with a weighted average of $0.4963. This insider purchase comes as the stock trades near its 52-week low of $0.40, having declined 89% over the past year.
Following the purchase, Schimmel indirectly holds 779,143 shares through the Schimmel Revocable Trust. He also directly owns 8,890 shares and indirectly holds 1,413,023 shares through the Paul Schimmel Prototype PSP.
According to Bond.az analysis, ATYR appears undervalued at current levels, with a Fair Value estimate of $0.61.
In other news, aTyr Pharma is planning a new Phase 3 study for its drug efzofitimod in chronic symptomatic pulmonary sarcoidosis. The company intends to file an investigational new drug application in June 2026.
